Cargando…

Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?

Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaborowska, Magdalena, Szmit, Sebastian, Szczylik, Cezary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400918/
https://www.ncbi.nlm.nih.gov/pubmed/22852011
http://dx.doi.org/10.5114/aoms.2012.29408
_version_ 1782238547180257280
author Zaborowska, Magdalena
Szmit, Sebastian
Szczylik, Cezary
author_facet Zaborowska, Magdalena
Szmit, Sebastian
Szczylik, Cezary
author_sort Zaborowska, Magdalena
collection PubMed
description Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors’ critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
format Online
Article
Text
id pubmed-3400918
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-34009182012-07-31 Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option? Zaborowska, Magdalena Szmit, Sebastian Szczylik, Cezary Arch Med Sci State of the Art Paper Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors’ critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer. Termedia Publishing House 2012-07-04 2012-07-04 /pmc/articles/PMC3400918/ /pubmed/22852011 http://dx.doi.org/10.5114/aoms.2012.29408 Text en Copyright © 2012 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle State of the Art Paper
Zaborowska, Magdalena
Szmit, Sebastian
Szczylik, Cezary
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title_full Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title_fullStr Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title_full_unstemmed Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title_short Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
title_sort sorafenib in progressive castrate-resistant prostate cancer. can we talk about a new therapeutic option?
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400918/
https://www.ncbi.nlm.nih.gov/pubmed/22852011
http://dx.doi.org/10.5114/aoms.2012.29408
work_keys_str_mv AT zaborowskamagdalena sorafenibinprogressivecastrateresistantprostatecancercanwetalkaboutanewtherapeuticoption
AT szmitsebastian sorafenibinprogressivecastrateresistantprostatecancercanwetalkaboutanewtherapeuticoption
AT szczylikcezary sorafenibinprogressivecastrateresistantprostatecancercanwetalkaboutanewtherapeuticoption